2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
14
Recruiting
8
Terminated
6
Active not recruiting
3
Withdrawn
2
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
1871
Neoplasms
1257
Colorectal Neoplasms
1057
Carcinoma, Non-Small-Cell Lung
1012
Stomach Neoplasms
802
Carcinoma, Hepatocellular
785
Lung Neoplasms
769
Prostatic Neoplasms
697
Pancreatic Neoplasms
577
Rectal Neoplasms
449
Ovarian Neoplasms
406
Colonic Neoplasms
405
Neoplasm Metastasis
403
Uterine Cervical Neoplasms
400
Recurrence
382
Leukemia, Myeloid, Acute
372
Esophageal Neoplasms
363
Multiple Myeloma
339
Lymphoma
335
Head and Neck Neoplasms
330
Melanoma
312
Precursor Cell Lymphoblastic Leukemia-Lymphoma
292
Brain Neoplasms
264
Urinary Bladder Neoplasms
256
Liver Neoplasms
225
Nasopharyngeal Carcinoma
223
Leukemia
218
Lymphoma, Large B-Cell, Diffuse
216
Polycystic Ovary Syndrome
210
Squamous Cell Carcinoma of Head and Neck
205
Interventions
tislelizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Urinary Bladder Diseases
×
Clear all
NCT04922047
2021-06-11
TACBIN-01
RenJi Hospital
Phase 1/2
Unknown
6 enrolled